[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP2526199A4 - Methods of generating zinc finger nucleases having altered activity - Google Patents

Methods of generating zinc finger nucleases having altered activity

Info

Publication number
EP2526199A4
EP2526199A4 EP11735277.3A EP11735277A EP2526199A4 EP 2526199 A4 EP2526199 A4 EP 2526199A4 EP 11735277 A EP11735277 A EP 11735277A EP 2526199 A4 EP2526199 A4 EP 2526199A4
Authority
EP
European Patent Office
Prior art keywords
methods
zinc finger
catalytic activity
zfn
altered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11735277.3A
Other languages
German (de)
French (fr)
Other versions
EP2526199A2 (en
Inventor
Iii Carlos F Barbas
Jing Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of EP2526199A2 publication Critical patent/EP2526199A2/en
Publication of EP2526199A4 publication Critical patent/EP2526199A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided herein are zinc linger nucleases having altered, arid in particular, improved catalytic activity and methods of generating such nucleases. Accordingly, there are provided methods for identifying improved catalytic activity of a ZFN by expressing a mutated zinc finger nuclease in a cell containing a reporter construct with a toxic gene, and a zinc finger nuclease cleavage site that is recognized by the ZFN. Survival of the cell is positively correlated with catalytic activity of the ZFN; thus, libraries of mutated ZFKs may be selected for altered catalytic activity based on relative survival rates, Methods of using identified ZFNs are also provided.
EP11735277.3A 2010-01-22 2011-01-21 Methods of generating zinc finger nucleases having altered activity Withdrawn EP2526199A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29759810P 2010-01-22 2010-01-22
US32903510P 2010-04-28 2010-04-28
PCT/US2011/022154 WO2011091324A2 (en) 2010-01-22 2011-01-21 Methods of generating zinc finger nucleases having altered activity

Publications (2)

Publication Number Publication Date
EP2526199A2 EP2526199A2 (en) 2012-11-28
EP2526199A4 true EP2526199A4 (en) 2013-08-07

Family

ID=44307625

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11735277.3A Withdrawn EP2526199A4 (en) 2010-01-22 2011-01-21 Methods of generating zinc finger nucleases having altered activity

Country Status (2)

Country Link
EP (1) EP2526199A4 (en)
WO (1) WO2011091324A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102660642A (en) * 2012-04-24 2012-09-12 西北农林科技大学 Screening system for screening zinc finger protein
EP3289104B1 (en) 2015-04-29 2020-11-04 New York University Method for treating high-grade gliomas
WO2018183766A1 (en) * 2017-03-29 2018-10-04 Editas Medicine, Inc. Selection methods
KR20200016892A (en) 2017-06-09 2020-02-17 에디타스 메디신, 인코포레이티드 Engineered CAS9 Nuclease
CN108118059B (en) * 2017-12-30 2021-03-19 苏州金唯智生物科技有限公司 Improved promoter, vector composed of improved promoter and application of improved promoter
JP2022547699A (en) * 2019-09-12 2022-11-15 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Library screening method
WO2021222287A2 (en) 2020-04-28 2021-11-04 Intellia Therapeutics, Inc. Methods of in vitro cell delivery
JPWO2022097663A1 (en) * 2020-11-06 2022-05-12
IL303971A (en) 2020-12-23 2023-08-01 Intellia Therapeutics Inc Compositions and methods for reducing hla-a in a cell
BR112023012432A2 (en) 2020-12-23 2023-11-07 Intellia Therapeutics Inc COMPOSITIONS AND METHODS FOR GENETIC MODIFICATION OF CIITA IN A CELL
JP2024502036A (en) 2020-12-30 2024-01-17 インテリア セラピューティクス，インコーポレイテッド engineered T cells
JP2024515650A (en) 2021-04-17 2024-04-10 インテリア セラピューティクス，インコーポレーテッド Lipid Nanoparticle Compositions
EP4322921A1 (en) 2021-04-17 2024-02-21 Intellia Therapeutics, Inc. Lipid nanoparticle compositions
TW202309034A (en) 2021-04-17 2023-03-01 美商英特利亞醫療公司 Inhibitors of dna-dependent protein kinase and compositions and uses thereof
WO2023205148A1 (en) 2022-04-19 2023-10-26 Intellia Therapeutics, Inc. Chimeric antigen receptor compositions and uses
TW202409271A (en) 2022-06-16 2024-03-01 美商英特利亞醫療公司 Compositions and methods for reducing mhc class i in a cell
WO2024006955A1 (en) 2022-06-29 2024-01-04 Intellia Therapeutics, Inc. Engineered t cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139898A2 (en) * 2006-05-25 2007-12-06 Sangamo Biosciences, Inc. Variant foki cleavage half-domains

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4968498B2 (en) * 2002-01-23 2012-07-04 ユニバーシティ オブ ユタ リサーチ ファウンデーション Targeted chromosomal mutagenesis using zinc finger nuclease
US20090042186A1 (en) * 2005-05-06 2009-02-12 Alexander Mankin Mapping new sites for antibiotic action in the ribosome
EP2568048A1 (en) * 2007-06-29 2013-03-13 Pioneer Hi-Bred International, Inc. Methods for altering the genome of a monocot plant cell

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139898A2 (en) * 2006-05-25 2007-12-06 Sangamo Biosciences, Inc. Variant foki cleavage half-domains

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Structure-Based Engineering of the FokI DNA Cleavage Domain in the Context of a Chimeric Endonuclease: Towards Maximally Efficient ''Gene Editing'' Therapy", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 9, 1 May 2004 (2004-05-01), pages 272, XP004635080, ISSN: 1525-0016 *
JING GUO ET AL: "Directed Evolution of an Enhanced and Highly Efficient FokI Cleavage Domain for Zinc Finger Nucleases", JOURNAL OF MOLECULAR BIOLOGY, vol. 400, no. 1, 4 May 2010 (2010-05-04), pages 96 - 107, XP055065197, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2010.04.060 *
MANI M ET AL: "Design, engineering, and characterization of zinc finger nucleases", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 335, no. 2, 23 September 2005 (2005-09-23), pages 447 - 457, XP027230194, ISSN: 0006-291X, [retrieved on 20050811], DOI: 10.1016/J.BBRC.2005.07.089 *
URNOV F D ET AL: "Highly efficient endogenous human gene correction using designed zinc-finger nucleases", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 435, no. 7042, 2 June 2005 (2005-06-02), pages 646 - 651, XP002411069, ISSN: 0028-0836, DOI: 10.1038/NATURE03556 *

Also Published As

Publication number Publication date
WO2011091324A8 (en) 2012-08-30
WO2011091324A3 (en) 2011-12-22
EP2526199A2 (en) 2012-11-28
WO2011091324A2 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
EP2526199A4 (en) Methods of generating zinc finger nucleases having altered activity
MX2022009512A (en) Targeted disruption of the mhc cell receptor.
NZ750938A (en) Regulation of gene expression using engineered nucleases
MX352023B (en) Alpha-amylase variants and polynucleotides encoding same.
EA201171335A1 (en) VECTOR GENE
EP3613852A3 (en) Evaluation and improvement of nuclease cleavage specificity
WO2011072246A3 (en) Tal effector-mediated dna modification
WO2010107493A3 (en) Modification of cxcr4 using engineered zinc finger proteins
MX2013002048A (en) Conjugates, particles, compositions, and related methods.
TN2014000493A1 (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
MX351043B (en) Methods for genomic modification.
MX336846B (en) Targeted genomic alteration.
SG10201809566SA (en) Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
EP2750225A4 (en) Negative electrode mixture or gel electrolyte, and battery using said negative electrode mixture or said gel electrolyte
MX2015010875A (en) Recombinant micro-organism for use in method with increased product yield.
NZ701099A (en) Ketol-acid reductoisomerase enzymes and methods of use
MX2015012484A (en) Acetyl-coa carboxylase mutations.
EP2667435A4 (en) Graphite/carbon mixed material, carbon material for battery electrodes, and battery
EP2714933A4 (en) Methods using dna methylation for identifying a cell or a mixture of cells for prognosis and diagnosis of diseases, and for cell remediation therapies
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
WO2012061022A3 (en) Use of copper-nickel catalyst for dehalogenation of chlorofluorocompounds
NZ603029A (en) New methods for isolating tr1 cells
SG195170A1 (en) Methods of treating or preventing rheumatic disease
WO2012109527A3 (en) Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
Ernst et al. The morphology of craters on 433 Eros

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120813

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130710

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/14 20060101ALI20130704BHEP

Ipc: C12Q 1/34 20060101AFI20130704BHEP

Ipc: C12N 15/55 20060101ALI20130704BHEP

Ipc: C07K 14/47 20060101ALN20130704BHEP

Ipc: C12N 15/10 20060101ALN20130704BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20140917